Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and auto-immune disease patients reduce the proliferation of autologous- and allogeneic-stimulated lymphocytes in vitro.

Chiara Bocelli-Tyndall 1 L. Bracci 2 G. Spagnoli 2 A. Braccini 2 M. Bouchenaki 1 Rhodri Ceredig 3, 4 V. Pistoia 5 Ivan Martin 2 Alan Tyndall 1
1 Department of Rheumatology
2 Department of Biomedicine [Basel]
3 DKBW - Developmental and Molecular Immunology, Department of Clinical and Biological Sciences
4 HOTE GREFFON - Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098)
5 Laboratorio di Oncologia
Abstract : OBJECTIVES: To investigate the ability of bone marrow (BM)-derived mesenchymal stromal cells (BM-MSCs) in suppressing the proliferation of stimulated lymphocytes across a range of conditions including autologous BM-MSCs derived from autoimmune disease (AD) patients. METHODS: In vitro cultures of BM-MSCs from healthy donors and AD patients were established and characterized by their differentiation potential into adipocytes and osteoblasts, and their fibroblast-colony-forming unit (CFU-F) ability and phenotype by flow cytometry. BM-MSCs (irradiated and non-irradiated) from healthy and AD patients were tested for their ability to suppress the in vitro proliferation of autologous and allogeneic peripheral blood mononuclear cells (PBMC) (from healthy donors and patients suffering from various ADs) stimulated with anti-CD3epsilon antibody alone or in combination with anti-CD28 antibody. The anti-proliferative effect of the BM-MSCs from healthy donors was tested also on transformed B-cell lines as a model of non-antigen-stimulated lymphocytes. RESULTS: BM-MSCs from healthy donors and AD patients reduced the proliferation of autologous and allogeneic PBMCs by up to 90% in a cell dose-dependent fashion. The immunosuppression was independent of the proliferation of the BM-MSCs and was also effective on already proliferating cells. It was independent also of the clinical activity of AD. An MSC dose-dependent pattern of suppression of proliferation was observed also with transformed B-cell lines, similar to that observed with proliferating PBMC. CONCLUSIONS: The BM-MSCs exhibit extensive anti-proliferative properties against lymphocytes under different conditions. This property might offer a form of immunomodulatory cellular therapy for AD patients if further confirmed in animal models.
Type de document :
Article dans une revue
Rheumatology, Oxford University Press (OUP), 2007, 46 (3), pp.403-8. 〈10.1093/rheumatology/kel267〉
Liste complète des métadonnées
http://www.hal.inserm.fr/inserm-00479753
Contributeur : Philippe Saas <>
Soumis le : dimanche 2 mai 2010 - 15:12:51
Dernière modification le : lundi 9 juillet 2018 - 13:12:02

Lien texte intégral

openaccess

Identifiants

Collections

UNIV-FCOMTE | UMR645

Citation

Chiara Bocelli-Tyndall, L. Bracci, G. Spagnoli, A. Braccini, M. Bouchenaki, et al.. Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and auto-immune disease patients reduce the proliferation of autologous- and allogeneic-stimulated lymphocytes in vitro.. Rheumatology, Oxford University Press (OUP), 2007, 46 (3), pp.403-8. 〈10.1093/rheumatology/kel267〉. 〈inserm-00479753〉

Exporter

BibTeX TEI DC DCterms EndNote

Partager

Métriques

Consultations de la notice

61

Contact

support.ccsd.cnrs.fr
hal.support@ccsd.cnrs.fr
Logo CCSD